Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer
Brain, lung, and colon tissue experience deleterious immune-related adverse events when immune-oncological agents or radiation are administered. However, there is a paucity of information regarding whether the addition of radiation to immuno-oncological regimens exacerbates the tissue inflammatory r...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.01504/full |
| id |
doaj-b0ce4e12c6224fa2a7b1602d3d9d9d8b |
|---|---|
| record_format |
Article |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Kelly J. McKelvey Kelly J. McKelvey Kelly J. McKelvey Amanda L. Hudson Amanda L. Hudson Amanda L. Hudson Ramyashree Prasanna Kumar Ramyashree Prasanna Kumar Thomas Eade Stephen J. Clarke Stephen J. Clarke Stephen J. Clarke Helen R. Wheeler Helen R. Wheeler Helen R. Wheeler Helen R. Wheeler Connie I. Diakos Connie I. Diakos Connie I. Diakos Viive M. Howell Viive M. Howell Viive M. Howell |
| spellingShingle |
Kelly J. McKelvey Kelly J. McKelvey Kelly J. McKelvey Amanda L. Hudson Amanda L. Hudson Amanda L. Hudson Ramyashree Prasanna Kumar Ramyashree Prasanna Kumar Thomas Eade Stephen J. Clarke Stephen J. Clarke Stephen J. Clarke Helen R. Wheeler Helen R. Wheeler Helen R. Wheeler Helen R. Wheeler Connie I. Diakos Connie I. Diakos Connie I. Diakos Viive M. Howell Viive M. Howell Viive M. Howell Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer Frontiers in Oncology cancer radiation immunotherapy inflammation toxicity |
| author_facet |
Kelly J. McKelvey Kelly J. McKelvey Kelly J. McKelvey Amanda L. Hudson Amanda L. Hudson Amanda L. Hudson Ramyashree Prasanna Kumar Ramyashree Prasanna Kumar Thomas Eade Stephen J. Clarke Stephen J. Clarke Stephen J. Clarke Helen R. Wheeler Helen R. Wheeler Helen R. Wheeler Helen R. Wheeler Connie I. Diakos Connie I. Diakos Connie I. Diakos Viive M. Howell Viive M. Howell Viive M. Howell |
| author_sort |
Kelly J. McKelvey |
| title |
Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer |
| title_short |
Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer |
| title_full |
Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer |
| title_fullStr |
Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer |
| title_full_unstemmed |
Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer |
| title_sort |
sub-acute toxicity in non-cancerous tissue and immune-related adverse events of a novel combination therapy for cancer |
| publisher |
Frontiers Media S.A. |
| series |
Frontiers in Oncology |
| issn |
2234-943X |
| publishDate |
2020-01-01 |
| description |
Brain, lung, and colon tissue experience deleterious immune-related adverse events when immune-oncological agents or radiation are administered. However, there is a paucity of information regarding whether the addition of radiation to immuno-oncological regimens exacerbates the tissue inflammatory response. We used a murine model to evaluate sub-acute tissue damage and the systemic immune response in C57Bl/6 mice when administered systemic anti-programmed cell death protein 1 (αPD-1) immunotherapy alone or in combination with stereotactic fractionated 10 gray/5 X-ray radiation to normal brain, lung or colon tissue. The model indicated that combinatorial αPD-1 immunotherapy and radiation may alter normal colon cell proliferation and cerebral blood vasculature, and induce systemic thrombocytopenia, lymphopenia, immune suppression, and altered immune repertoire (including interleukin-1β). Therein our data supports close monitoring of hematological and immune-related adverse events in patients receiving combination therapy. |
| topic |
cancer radiation immunotherapy inflammation toxicity |
| url |
https://www.frontiersin.org/article/10.3389/fonc.2019.01504/full |
| work_keys_str_mv |
AT kellyjmckelvey subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer AT kellyjmckelvey subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer AT kellyjmckelvey subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer AT amandalhudson subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer AT amandalhudson subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer AT amandalhudson subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer AT ramyashreeprasannakumar subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer AT ramyashreeprasannakumar subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer AT thomaseade subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer AT stephenjclarke subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer AT stephenjclarke subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer AT stephenjclarke subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer AT helenrwheeler subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer AT helenrwheeler subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer AT helenrwheeler subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer AT helenrwheeler subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer AT connieidiakos subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer AT connieidiakos subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer AT connieidiakos subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer AT viivemhowell subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer AT viivemhowell subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer AT viivemhowell subacutetoxicityinnoncanceroustissueandimmunerelatedadverseeventsofanovelcombinationtherapyforcancer |
| _version_ |
1725243463872544768 |
| spelling |
doaj-b0ce4e12c6224fa2a7b1602d3d9d9d8b2020-11-25T00:51:53ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-01-01910.3389/fonc.2019.01504491653Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for CancerKelly J. McKelvey0Kelly J. McKelvey1Kelly J. McKelvey2Amanda L. Hudson3Amanda L. Hudson4Amanda L. Hudson5Ramyashree Prasanna Kumar6Ramyashree Prasanna Kumar7Thomas Eade8Stephen J. Clarke9Stephen J. Clarke10Stephen J. Clarke11Helen R. Wheeler12Helen R. Wheeler13Helen R. Wheeler14Helen R. Wheeler15Connie I. Diakos16Connie I. Diakos17Connie I. Diakos18Viive M. Howell19Viive M. Howell20Viive M. Howell21Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, The University of Sydney Northern Clinical School and Northern Sydney Local Health District, St Leonards, NSW, AustraliaSydney Vital Translational Cancer Research Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaThe Brain Cancer Group, St Leonards, NSW, AustraliaBill Walsh Translational Cancer Research Laboratory, Kolling Institute, The University of Sydney Northern Clinical School and Northern Sydney Local Health District, St Leonards, NSW, AustraliaSydney Vital Translational Cancer Research Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaThe Brain Cancer Group, St Leonards, NSW, AustraliaBill Walsh Translational Cancer Research Laboratory, Kolling Institute, The University of Sydney Northern Clinical School and Northern Sydney Local Health District, St Leonards, NSW, AustraliaSydney Vital Translational Cancer Research Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaBill Walsh Translational Cancer Research Laboratory, Kolling Institute, The University of Sydney Northern Clinical School and Northern Sydney Local Health District, St Leonards, NSW, AustraliaSydney Vital Translational Cancer Research Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaBill Walsh Translational Cancer Research Laboratory, Kolling Institute, The University of Sydney Northern Clinical School and Northern Sydney Local Health District, St Leonards, NSW, AustraliaSydney Vital Translational Cancer Research Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaThe Brain Cancer Group, St Leonards, NSW, AustraliaNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaBill Walsh Translational Cancer Research Laboratory, Kolling Institute, The University of Sydney Northern Clinical School and Northern Sydney Local Health District, St Leonards, NSW, AustraliaSydney Vital Translational Cancer Research Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaBill Walsh Translational Cancer Research Laboratory, Kolling Institute, The University of Sydney Northern Clinical School and Northern Sydney Local Health District, St Leonards, NSW, AustraliaSydney Vital Translational Cancer Research Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaThe Brain Cancer Group, St Leonards, NSW, AustraliaBrain, lung, and colon tissue experience deleterious immune-related adverse events when immune-oncological agents or radiation are administered. However, there is a paucity of information regarding whether the addition of radiation to immuno-oncological regimens exacerbates the tissue inflammatory response. We used a murine model to evaluate sub-acute tissue damage and the systemic immune response in C57Bl/6 mice when administered systemic anti-programmed cell death protein 1 (αPD-1) immunotherapy alone or in combination with stereotactic fractionated 10 gray/5 X-ray radiation to normal brain, lung or colon tissue. The model indicated that combinatorial αPD-1 immunotherapy and radiation may alter normal colon cell proliferation and cerebral blood vasculature, and induce systemic thrombocytopenia, lymphopenia, immune suppression, and altered immune repertoire (including interleukin-1β). Therein our data supports close monitoring of hematological and immune-related adverse events in patients receiving combination therapy.https://www.frontiersin.org/article/10.3389/fonc.2019.01504/fullcancerradiationimmunotherapyinflammationtoxicity |